Enovis (NYSE:ENOV) Rating Lowered to Hold at Wall Street Zen

Enovis (NYSE:ENOV) was downgraded by stock analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research note issued on Saturday, Wall Street Zen reports.

ENOV has been the subject of several other research reports. Wells Fargo & Company lowered their price target on Enovis from $39.00 to $33.00 and set an “overweight” rating for the company in a research note on Wednesday, September 2nd. Citizens Jmp dropped their price objective on Enovis from $55.00 to $47.00 and set a “market outperform” rating on the stock in a report on Wednesday, September 2nd. BTIG Research cut their price objective on shares of Enovis from $40.00 to $36.00 and set a “buy” rating on the stock in a research report on Tuesday, September 1st. Zacks Research upgraded shares of Enovis from a “strong sell” rating to a “hold” rating in a research note on Wednesday, July 29th. Finally, UBS Group reiterated a “buy” rating and issued a $44.00 target price on shares of Enovis in a research note on Monday, October 5th. Ten equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $39.50.

Enovis Price Performance

ENOV opened at $17.72 on Friday. The stock has a fifty day moving average price of $21.74 and a 200 day moving average price of $23.29. The company has a current ratio of 1.98, a quick ratio of 1.00 and a debt-to-equity ratio of 0.84. Enovis has a 1 year low of $16.70 and a 1 year high of $34.28. The stock has a market cap of $1.02 billion, a price-to-earnings ratio of -0.92 and a beta of 1.37.

Enovis (NYSE:ENOV) last issued its earnings results on Thursday, August 6th. The company reported $0.90 earnings per share for the quarter, topping the consensus estimate of $0.85 by $0.05. Enovis had a positive return on equity of 12.03% and a negative net margin of 47.96%. The company had revenue of $582.78 million for the quarter, compared to analyst estimates of $581.84 million. During the same period in the prior year, the firm posted $0.79 EPS. The business’s revenue was up 3.2% compared to the same quarter last year. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. Analysts forecast that Enovis will post 3.15 EPS for the current fiscal year.

Insider Buying and Selling at Enovis

In related news, CEO Damien Mcdonald purchased 13,035 shares of Enovis stock in a transaction on Friday, September 4th. The stock was bought at an average price of $19.15 per share, with a total value of $249,620.25. Following the completion of the transaction, the chief executive officer directly owned 247,077 shares of the company’s stock, valued at approximately $4,731,524.55. This represents a 5.57% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Oliver Engert purchased 5,140 shares of the firm’s stock in a transaction dated Thursday, September 3rd. The shares were bought at an average price of $19.46 per share, with a total value of $100,024.40. Following the purchase, the insider owned 61,238 shares in the company, valued at $1,191,691.48. This represents a 9.16% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have acquired 23,293 shares of company stock worth $449,599 over the last three months. Company insiders own 2.90% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Paradigm Capital Management Inc. NY lifted its position in Enovis by 70.2% during the 1st quarter. Paradigm Capital Management Inc. NY now owns 1,776,715 shares of the company’s stock worth $40,420,000 after acquiring an additional 732,917 shares during the last quarter. River Road Asset Management LLC boosted its holdings in Enovis by 3.2% during the fourth quarter. River Road Asset Management LLC now owns 1,487,277 shares of the company’s stock valued at $39,621,000 after acquiring an additional 46,289 shares during the period. Private Management Group Inc. boosted its holdings in Enovis by 38.8% during the second quarter. Private Management Group Inc. now owns 1,365,082 shares of the company’s stock valued at $28,257,000 after acquiring an additional 381,705 shares during the period. Allspring Global Investments Holdings LLC boosted its holdings in Enovis by 38.0% during the first quarter. Allspring Global Investments Holdings LLC now owns 1,045,360 shares of the company’s stock valued at $24,430,000 after acquiring an additional 287,687 shares during the period. Finally, Invenomic Capital Management LP grew its position in shares of Enovis by 6.2% in the fourth quarter. Invenomic Capital Management LP now owns 756,717 shares of the company’s stock valued at $20,159,000 after purchasing an additional 44,048 shares during the last quarter. Institutional investors and hedge funds own 98.45% of the company’s stock.

Enovis Company Profile

Enovis Corporation is a medical technology company that develops, manufactures and distributes products designed to improve patient outcomes and support the restoration of movement. Its portfolio serves orthopedic, rehabilitation and recovery markets, with products used by physicians, hospitals, physical therapists, athletic trainers and consumers.

The company’s offerings include orthopedic braces and supports, cold and compression therapy systems, rehabilitation equipment, electrical stimulation and ultrasound products, surgical implants and related technologies.